Levels and trends in cardiovascular risk factors and drug treatment in 4837 elderly Dutch myocardial infarction patients between 2002 and 2006

Netherlands Heart Journal

Volumn 20, Issue 3, 2012, Pages 102-109

  Soedamah Muthu, S S ^a   Geleijnse, J M ^a   Giltay, E J ^b   de Goede, J ^a   Oude Griep, L M ^a   Waterham, E ^a   Teitsma Jansen, A M ^a   Mulder, B J M ^c   de Boer, M J ^d   Deckers, J W ^e   Zock, P L ^f   Kromhout, D ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNILEVER RESEARCH VLAARDINGEN   (Netherlands)

Author keywords

Coronary heart disease patients; Medication; Myocardial infarction; Risk factors; Trends

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; SULFONAMIDE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIET; FEMALE; GENDER; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; QUESTIONNAIRE; SMOKING;

EID: 84859641516     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-012-0248-z     Document Type: Article

References (19)

1. Mackay J, Mensah G, WHO. The atlas of heart disease and stroke. 1st ed. Geneva: World Health Organization; 2004.
2. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747-57.
3. Vaartjes I, van Dis I, Visseren FLJ, et al. (2009) Cardiovascular diseases in the Netherlands, 2009. In: Visseren FLJ, van Dis I (ed) Netherlands Heart Foundation Hart-en Vaatziekten in Nederland the Hague, the Netherlands: Dutch heart foundation
4. Davies AR, Smeeth L, Grundy EM. Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996 2005. Eur Heart J. 2007;28:2142-7.
5. Arveiler D, Wagner A, Ducimetiere P, et al. Trends in coronary heart disease in France during the second half of the 1990s. Eur J Cardiovasc Prev Rehabil. 2005;12:209-15.
6. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373:929-40.
7. Geleijnse JM, Giltay EJ, Schouten EG, et al. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. Am Heart J. 2010;159:539-46.
8. Kromhout D, Giltay EJ, Geleijnse JM. N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015-26.
9. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
11. WHO. WHO Collaborating Centre for Drug Statistics Methodology, Anatomical Therapeutic Chemical Classification System (ATC). World Health Organization, Oslo (2009).
12. Tukey JW. Some selected quick and easy methods of statistical analysis. Trans N Y Acad Sci. 1953;16:88-97.
13. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005;365:82-93.
14. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008;51:37-45.
15. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790-7.
16. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1-S113.
17. Iestra JA, Kromhout D, van der Schouw YT, et al. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation. 2005;112:924-34.
18. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7:e1000252.
19. Leon H, Shibata MC, Sivakumaran S, et al. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ (Clinical research ed). 2008;337:a2931.